Who Should Not Take Tirzepatide? Contraindications and Screening

Tirzepatide has some of the strongest weight-loss data of any medication studied to date. In the SURMOUNT-1 trial published in the New England Journal of Medicine, participants using the 15 mg dose lost a mean of 20.9% of body weight over 72 weeks. That is a meaningful number, and it reflects the biology of a dual GIP and GLP-1 receptor agonist doing what it is designed to do: reduce appetite signals, slow gastric emptying, and quiet the constant mental chatter about food that researchers sometimes call food noise. But tirzepatide is not the right tool for everyone. Before any prescription is written, a provider needs to rule out specific contraindications and weigh individual risk factors. This post walks through exactly who should not take tirzepatide, who needs extra caution, and how screening works.

One clarification before we go further: this article discusses the tirzepatide molecule and its clinical evidence. Compounded tirzepatide is prepared by a US-licensed compounding pharmacy under a valid prescription. It is not an FDA-approved finished drug product, and it is distinct from the FDA-approved brand-name products Zepbound and Mounjaro. The efficacy figures cited here come from the SURMOUNT and SURPASS clinical trials and represent what was observed with the molecule in those studies, not results from any compounding pharmacy or telehealth platform.

Absolute Contraindications: When Tirzepatide Is Off the Table

Some conditions make tirzepatide unsafe regardless of how much weight someone needs to lose. These are not judgment calls or borderline situations. If any of the following apply, a responsible provider will not prescribe tirzepatide, and you should be skeptical of any platform that does not ask about them.

• Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 receptor agonists caused thyroid C-cell tumors in rodent studies. The clinical significance in humans is still being studied, but the FDA-approved labeling carries a boxed warning for this reason. The risk is considered unacceptable for anyone with a personal history of MTC or a family history of it.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 is a genetic condition that markedly elevates MTC risk. The same boxed warning applies.
• Known hypersensitivity to tirzepatide or any excipient in the formulation. Serious allergic reactions including anaphylaxis have been reported. If you have had a confirmed reaction to a GLP-1 or GIP receptor agonist previously, this is a contraindication.
• Pregnancy. Tirzepatide is not approved for use during pregnancy. Animal studies showed fetal harm. Women who are pregnant should not use tirzepatide, and women of childbearing age should discuss contraception with their provider, since GLP-1 agonists may reduce the absorption of oral contraceptives when nausea and vomiting are present.

Serious Cautions: Not Automatic Disqualifiers, but Reasons for a Careful Conversation

Below the level of hard contraindications are conditions that require a provider to take a closer look and potentially modify the approach, monitor more closely, or decide the risk-benefit balance does not favor tirzepatide for a particular person.

• Pancreatitis history. GLP-1 receptor agonists have been associated with acute pancreatitis. Anyone with a history of pancreatitis, especially recurrent episodes or pancreatitis linked to gallstones or alcohol, warrants careful evaluation. Tirzepatide is generally avoided in this population.
• Gastroparesis or severe gastrointestinal motility disorders. Tirzepatide slows gastric emptying as part of its mechanism. In someone who already has delayed gastric emptying, this can worsen symptoms significantly, complicate blood glucose management, and create serious complications around anesthesia.
• Type 1 diabetes. Tirzepatide is studied primarily in people with type 2 diabetes and in people with obesity without diabetes. Its use in type 1 diabetes is not well characterized. The risk of hypoglycemia and diabetic ketoacidosis requires specialized management.
• Severe kidney or liver disease. Tirzepatide exposure increases in severe renal or hepatic impairment. Clinical data in these populations are limited, and a provider needs to weigh whether that exposure shift changes the safety profile meaningfully for a given individual.
• Gallbladder disease. Rapid weight loss of any kind increases gallstone risk. GLP-1 agonists have been associated with gallbladder events including cholecystitis. Someone with existing gallbladder disease or a prior history of stones should discuss this risk explicitly.
• Diabetic retinopathy. Rapid improvements in blood glucose control, which can occur with tirzepatide in people with type 2 diabetes, have occasionally been associated with worsening of diabetic eye disease. If you have retinopathy, your provider should know before prescribing.
• Eating disorders. Tirzepatide suppresses appetite substantially. In someone with a current or recent restrictive eating disorder, this effect could be dangerous. A thorough mental health history is part of responsible screening.

This list is not exhaustive. Your medication list matters too. If you take insulin or a sulfonylurea for diabetes, adding tirzepatide significantly increases hypoglycemia risk and those medications typically need to be adjusted. Certain other medications that slow gastric motility can have compounded effects. A provider reviewing your full intake form is the only way to catch interactions that a general article cannot anticipate.

What Honest Screening Actually Looks Like

If you have been burned by telehealth platforms that approved you in 90 seconds without asking about your medical history, you know the feeling of wondering whether anyone actually looked at your chart. Responsible prescribing for tirzepatide requires a review of your health history, current medications, relevant family history, and your goals. It is not a checkbox. It is a clinical judgment.

At a minimum, a screening process should ask about thyroid cancer history in you and your family, any history of pancreatitis, current or past GI conditions, pregnancy status and plans, current medications including insulin and oral hypoglycemics, and any known allergies to this class of medication. If a platform is not asking these questions before prescribing, that is a problem worth taking seriously.

It is also worth naming that being screened out is not a failure. Chronic obesity is driven by biology, not willpower. Research including the NIH Biggest Loser study led by Fothergill and colleagues in 2016 showed that the body actively fights weight loss by suppressing metabolism and increasing hunger hormones, sometimes for years after dieting ends. That is not a character flaw. If tirzepatide is not appropriate for you, the right provider helps you understand why and what options do make sense, rather than just leaving you with a declined form.

Side Effects to Know Before You Start

Even for people who are appropriate candidates, tirzepatide causes side effects for many users, particularly in the early weeks of dose escalation. Nausea is the most common and affects a significant portion of people starting the medication. Vomiting, diarrhea, constipation, and reduced appetite beyond what you expect are also common. Most GI side effects improve as the body adjusts and as the dose is titrated slowly. More serious but less common risks include the pancreatitis and gallbladder events noted above, as well as heart rate increases that have been observed in some studies. The SURMOUNT-1 data showed a meaningful discontinuation rate due to adverse events, which means some people do stop the medication because of how it makes them feel. That is honest information you deserve to have before starting, not after.

The goal is not to scare you away from a medication that, for the right candidate, can produce a meaningful and biology-driven change in weight and metabolic health. The goal is to make sure you go in with accurate expectations and that someone with a license and clinical judgment has actually evaluated your specific situation.